<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JDR</journal-id>
<journal-id journal-id-type="hwp">spjdr</journal-id>
<journal-id journal-id-type="nlm-ta">J Dent Res</journal-id>
<journal-title>Journal of Dental Research</journal-title>
<issn pub-type="ppub">0022-0345</issn>
<issn pub-type="epub">1544-0591</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0022034512451026</article-id>
<article-id pub-id-type="publisher-id">10.1177_0022034512451026</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Reports</subject>
<subj-group subj-group-type="heading">
<subject>Biological</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Effect of Reveromycin A on Experimental Tooth Movement in OPG−/− Mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Tanaka</surname><given-names>M.</given-names></name>
<xref ref-type="aff" rid="aff1-0022034512451026">1</xref>
<xref ref-type="corresp" rid="corresp1-0022034512451026">*</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Miyazawa</surname><given-names>K.</given-names></name>
<xref ref-type="aff" rid="aff1-0022034512451026">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tabuchi</surname><given-names>M.</given-names></name>
<xref ref-type="aff" rid="aff1-0022034512451026">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yabumoto</surname><given-names>T.</given-names></name>
<xref ref-type="aff" rid="aff1-0022034512451026">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kadota</surname><given-names>M.</given-names></name>
<xref ref-type="aff" rid="aff1-0022034512451026">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yoshizako</surname><given-names>M.</given-names></name>
<xref ref-type="aff" rid="aff1-0022034512451026">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yamane</surname><given-names>C.</given-names></name>
<xref ref-type="aff" rid="aff1-0022034512451026">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kawatani</surname><given-names>M.</given-names></name>
<xref ref-type="aff" rid="aff2-0022034512451026">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Osada</surname><given-names>H.</given-names></name>
<xref ref-type="aff" rid="aff2-0022034512451026">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Maeda</surname><given-names>H.</given-names></name>
<xref ref-type="aff" rid="aff3-0022034512451026">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Goto</surname><given-names>S.</given-names></name>
<xref ref-type="aff" rid="aff1-0022034512451026">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0022034512451026"><label>1</label>Department of Orthodontics, School of Dentistry, Aichi-Gakuin University, 2-11 Suemori-Dori, Chikusa-ku, Nagoya 464-8651, Japan</aff>
<aff id="aff2-0022034512451026"><label>2</label>Chemical Biology Core Facility, RIKEN ASI, 2-1 Hirosawa, Japan</aff>
<aff id="aff3-0022034512451026"><label>3</label>Department of Oral Pathology, School of Dentistry, Aichi-Gakuin University, Chikusa-ku, Nagoya 464-8650, Japan</aff>
<author-notes>
<corresp id="corresp1-0022034512451026"><label>*</label><email>miumiu@dpc.agu.ac.jp</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>91</volume>
<issue>8</issue>
<fpage>771</fpage>
<lpage>776</lpage>
<history>
<date date-type="received">
<day>12</day>
<month>2</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>9</day>
<month>5</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>5</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 International &amp; American Associations for Dental Research</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">International &amp; American Associations for Dental Research</copyright-holder>
</permissions>
<abstract>
<p>In osteoprotegerin-deficient (OPG−/−) mice, osteoclast activity causes bone resorption to outpace bone formation, leading to the development of severe osteoporosis. Such mice are therefore useful for investigating the alveolar bone of patients with osteoporosis. Reveromycin A (RM-A) was recently identified as the unique agent acting on osteoclast activation. This study aimed to analyze the effect of RM-A on the orthodontic treatment of OPG−/− mice (a model of osteoporosis patients with high levels of bone turnover). We examined alveolar bone remodeling in OPG−/− and wild-type (WT) mice during continuous tooth movement. The orthodontic force was induced by means of a Ni-Ti closed-coil spring to move the maxillary first molar for 14 days. RM-A sodium salt (1 mg/kg) was administered intraperitoneally twice daily. In OPG−/− mice, the tooth movement distance was longer, alveolar bone resorption was enhanced, the osteoclast count was greater, and serum alkaline phosphatase and tartrate-resistant acid phosphatase levels were higher relative to those in WT mice. However, the administration of RM-A in OPG−/− mice reduced these parameters. We conclude that RM-A normalizes bone metabolism and loss of alveolar bone during continuous tooth movement in OPG−/− mice.</p>
</abstract>
<kwd-group>
<kwd>bone remodeling/regeneration</kwd>
<kwd>osteoblast</kwd>
<kwd>osteoclast</kwd>
<kwd>orthodontic</kwd>
<kwd>osteoporosis</kwd>
<kwd>periodontal disease/periodontitis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0022034512451026" sec-type="intro">
<title>Introduction</title>
<p>Recently, the need for orthodontic treatment has been expanded for the prevention of periodontal disease or pre-prosthetic surgery, in not only healthy people but also patients with systemic diseases such as osteoporosis (<xref ref-type="bibr" rid="bibr25-0022034512451026">Zahrowski, 2009</xref>). During orthodontic treatment, tooth movement involves the resorption of alveolar bone by osteoclasts on the pressure side and its formation by osteoblasts on the tension side, leading to alterations of the surrounding tissue (<xref ref-type="bibr" rid="bibr21-0022034512451026">Yokoya <italic>et al</italic>., 1997</xref>; <xref ref-type="bibr" rid="bibr16-0022034512451026">Sato <italic>et al</italic>., 2000</xref>). Optimal tooth movement and bone healing, which are dependent on osteoclastic and osteoblastic activity, are important for successful orthodontic treatment (<xref ref-type="bibr" rid="bibr25-0022034512451026">Zahrowski, 2009</xref>).</p>
<p>To elucidate the alveolar bone metabolism of high-turnover osteoporosis patients, we focused on osteoprotegerin-deficient (OPG−/−) mice, which are a model of juvenile Paget’s disease that exhibit severe osteoporosis from enhanced osteoclastogenesis. Compared with wild-type (WT) mice, adult OPG−/− mice also have lower bone mineral density, characterized by severe trabecular and cortical bone porosity and a high incidence of fractures (<xref ref-type="bibr" rid="bibr1-0022034512451026">Bucay <italic>et al</italic>., 1998</xref>; <xref ref-type="bibr" rid="bibr8-0022034512451026">Mizuno <italic>et al</italic>., 1998</xref>).</p>
<p>Bisphosphonates (BPs) are often prescribed to treat osteoporosis or Paget’s disease. Some BPs bind rapidly and tightly to bone mineral before being incorporated by osteoclasts during bone resorption and inducing apoptosis (<xref ref-type="bibr" rid="bibr10-0022034512451026">Murakami <italic>et al</italic>., 1995</xref>; <xref ref-type="bibr" rid="bibr15-0022034512451026">Russell and Rogers, 1999</xref>). The effects of this therapy are therefore long-lived (<xref ref-type="bibr" rid="bibr25-0022034512451026">Zahrowski, 2009</xref>), so BP treatment is not advisable in orthodontics.</p>
<p>Recently, the unique agent Reveromycin A (RM-A) was reported to have specific activity toward osteoclasts. RM-A is an acid polyketide compound discovered in the culture medium of actinomycetes (<xref ref-type="bibr" rid="bibr12-0022034512451026">Osada <italic>et al</italic>., 1991</xref>). Treatment with RM-A was shown to markedly prevent bone loss in the distal metaphysis in ovariectomized (OVX) mice, an <italic>in vivo</italic> experimental model of post-menopausal osteoporosis. Moreover, RM-A was selectively absorbed into activated osteoclasts, which secrete acid to dissolve bone (<xref ref-type="bibr" rid="bibr20-0022034512451026">Woo <italic>et al</italic>., 2006</xref>). This effect does not occur in immature precursor cells or inactive osteoclasts. RM-A has been also used in ddY mice, and it has a high potential to inhibit bone resorption by inducing osteoclast apotosis <italic>via</italic> the suppression of isoleucyl-tRNA synthetase in osteoclasts (<xref ref-type="bibr" rid="bibr9-0022034512451026">Muguruma <italic>et al</italic>., 2005</xref>).</p>
<p>The purpose of this study was to identify the effect of RM-A on inhibiting bone resorption in OPG−/− mice, because the relationship between osteoclasts and osteoblasts and bone metabolism is not fully understood. We examined alveolar bone remodeling in OPG−/− and WT mice during continuous tooth movement to test our hypothesis that RM-A administration inhibits bone resorption and decreases tooth movement.</p>
</sec>
<sec id="section2-0022034512451026" sec-type="materials|methods">
<title>Materials &amp; Methods</title>
<sec id="section3-0022034512451026">
<title>Animals</title>
<p>Eight-week-old male OPG−/− (n = 8) and WT (C57BL/6J, n = 8) mice were used in the study (CLEA Japan, Osaka, Japan) and housed at the animal experimentation laboratory of the School of Dentistry, Aichi-Gakuin University, Japan. Room temperature and humidity were maintained at 22 ± 2°C and 50 ± 10%, respectively, and a 12-hour light/dark cycle was established. Mice were provided with free access to solid food (CE-2; CLEA Japan, Tokyo, Japan) and tap water. Animal care and experimental procedures were performed in accordance with the Guidelines for Animal Experiments of the School of Dentistry, Aichi-Gakuin University.</p>
</sec>
<sec id="section4-0022034512451026">
<title>Experimental Tooth Movement</title>
<p>Mice were anesthetized with diethylether during the setting and adjustment of the orthodontic appliance as detailed previously (<xref ref-type="bibr" rid="bibr23-0022034512451026">Yoshimatsu <italic>et al</italic>., 2006</xref>). The appliance was comprised of a Ni-Ti closed-coil spring consisting of a Ni-Ti wire of diameter 0.15 mm and a coil diameter of 0.9 mm. The appliance was inserted between the upper anterior alveolar bone and the upper left first molar and was fixed with stainless steel wire. According to the manufacturers, the force level of the coil spring after activation is approximately 10 g. The upper right first molar was unloaded.</p>
<p>RM-A sodium salt (1 mg/kg) was administered intraperitoneally twice daily beginning 3 days before appliance insertion to 4 animals in each of the OPG−/− and WT groups. As a control, an identical volume of physiological saline was administered to 4 animals in each of the OPG−/− and WT groups on the same day. The duration and interval of administration were determined according to a previous study (<xref ref-type="bibr" rid="bibr20-0022034512451026">Woo <italic>et al</italic>., 2006</xref>) (<xref ref-type="fig" rid="fig1-0022034512451026">Figs. 1A</xref>, <xref ref-type="fig" rid="fig1-0022034512451026">1B</xref>).</p>
<fig id="fig1-0022034512451026" position="float">
<label>Figure 1.</label>
<caption>
<p>Schematic diagram of spring insertion between the M1 (first molar) and incisors <bold>(A)</bold>. Photograph of spring insertion <bold>(B)</bold>. Schematic diagram of a horizontal section through the roots of M1 <bold>(C)</bold>. M1M; M1 mesial root, M1DP; M1 distopalatal root, M1DB; M1 distobuccal root.</p>
</caption>
<graphic xlink:href="10.1177_0022034512451026-fig1.tif"/></fig>
</sec>
<sec id="section5-0022034512451026">
<title>Micro-CT Scanning</title>
<p>On days 3 and 7, images of the bones were obtained by micro-CT scanning (R_mCT, Rigaku, Tokyo, Japan) under 1.5% isoflurane (Forane, Abbott, Tokyo, Japan) anesthesia. An x-ray of the maxilla was taken at 90 kV, 88 µA, for 2 min. Images were analyzed with TRI/3D-BON software (Ratoc System Engineering, Tokyo, Japan) to determine how far the teeth moved. Images were rotated and adjusted to ensure that the occlusal view with the narrowest gap between M1 and M2 was observed. To observe the state of the alveolar crest of the left M1 interradicular septum, we observed the roots of M1 and the surrounding alveolar bone in a sagittal view 14 days after insertion of the appliance.</p>
</sec>
<sec id="section6-0022034512451026">
<title>Pathohistological Observations</title>
<p>Maxillary bones were collected 14 days after insertion of the appliance and fixed in 10% neutral buffered formalin. Samples were decalcified for approximately 4 wks with 10% EDTA (pH 7.2) at 4°C, then embedded in paraffin by conventional methods and cut into 5-µm horizontal sections. The occlusal one-third of the region between the root furcation and apex was observed. Next, hematoxylin-eosin (HE) staining and tartrate-resistant acid phosphatase (TRAP) staining with an acid phosphatase leukocyte kit (Sigma, St. Louis, MO, USA) were carried out, and stained sections were observed by light microscopy.</p>
<p>The bone volume in the interradicular septum was measured as described previously, with minor modifications (<xref ref-type="bibr" rid="bibr18-0022034512451026">Sprogar <italic>et al</italic>., 2008</xref>). In our study, to exclude the influence of bone loss caused by the mechanical stress of wire surrounding the teeth, the borders of the tissue area examined were defined by the maxillary first molar mesial root (M1M), the maxillary first molar distopalatal root (M1DP), and the maxillary first molar distobuccal root (M1DB), and expressed as a percentage of the bone volume in the interradicular septum <italic>vs</italic>. the total volume of the area (<xref ref-type="fig" rid="fig1-0022034512451026">Fig. 1C</xref>). Osteoclast counts were performed for TRAP-stained sections of the M1DP alveolar bone surface.</p>
</sec>
<sec id="section7-0022034512451026">
<title>Serum ALP and TRAP</title>
<p>Blood was extracted from dead mice and used to analyze serum alkaline phosphatase (ALP) and TRAP levels. Serum ALP was measured with a commercial ALP kit (Liquitech ALP; Roche Diagnostic, Tokyo, Japan), and serum TRAP was measured with a commercial ELISA TRAP kit (Immunodiagnostic Systems Ltd, Boldon, UK).</p>
</sec>
<sec id="section8-0022034512451026">
<title>Statistical Analysis</title>
<p>All data are presented as means ± SEM, and statistical analysis was carried out by one-way analysis of variance (ANOVA; Tukey’s multiple comparison test). All statistical analysis were performed with Prism version 5 (GraphPad Software Inc., San Diego, CA, USA), and values of <italic>p</italic> &lt; 0.05 were considered to be significant.</p>
</sec></sec>
<sec id="section9-0022034512451026" sec-type="results">
<title>Results</title>
<sec id="section10-0022034512451026">
<title>RM-A Significantly Attenuated Experimental Tooth Movement in OPG −/− Mice</title>
<p>On days 3 and 7, there was no significant difference between the OPG−/− and WT groups in terms of the distance between M1 and M2. However, by day 14, the OPG−/− RM-A- group showed significantly greater movement of M1–M2 than the WT RM-A- group (<italic>p</italic> &lt; 0.001) (<xref ref-type="fig" rid="fig2-0022034512451026">Figs. 2A</xref>, <xref ref-type="fig" rid="fig2-0022034512451026">2B</xref>).</p>
<fig id="fig2-0022034512451026" position="float">
<label>Figure 2.</label>
<caption>
<p>Tooth movement in wild-type (WT) and OPG-deficient (OPG −/− mice) with (RM-A+) and without (RM-A-) RM-A administration. Representative microfocus x-ray CT images of M1 and M2 obtained 14 days after spring insertion <bold>(A)</bold>. Mean distance between M1 and M2 on days 0, 3, 7, and 14 after spring insertion (n.s., not significant; ***<italic>p</italic> &lt; 0.001) <bold>(B)</bold>. Representative microfocus x-ray CT images of the bone surrounding M1 14 days after spring insertion <bold>(C)</bold>.</p>
</caption>
<graphic xlink:href="10.1177_0022034512451026-fig2.tif"/></fig>
<p>For both the OPG−/− and WT groups, there was no significant difference between the RM-A+ and RM-A- subgroups in the movement of M1–M2 on day 7. At 14 days, the OPG−/− RM-A+ group had a significantly smaller distance between M1 and M2 than the OPG−/− RM-A- group (<italic>p</italic> &lt; 0.001). There was no significant difference between the RM-A+ and RM-A- subgroups of the WT group on day 14. There was no significant difference between the OPG−/− RM-A+ and WT RM-A- groups on day 14 (<xref ref-type="fig" rid="fig2-0022034512451026">Figs. 2A</xref>, <xref ref-type="fig" rid="fig2-0022034512451026">2B</xref>).</p>
</sec>
<sec id="section11-0022034512451026">
<title>RM-A Significantly Decreased Alveolar Bone Resorption in OPG−/− Mice</title>
<p>In the WT RM-A- group, there was no change in the quality of the trabecular bone in the left M1 furcation on day 14, but the OPG−/− RM-A- group showed considerable resorption of the alveolar bone at the M1 furcation (<xref ref-type="fig" rid="fig2-0022034512451026">Fig. 2C</xref>). At this same time-point, both groups showed enlargement on the tension side and narrowing on the pressure side of the periodontal ligament. However, there was a significant bone volume decrease in the interradicular septum of the OPG −/− RM-A- group compared with a slight decrease in the volume of surrounding alveolar bone in the WT RM-A- group (<xref ref-type="fig" rid="fig3-0022034512451026">Figs. 3A</xref>, <xref ref-type="fig" rid="fig3-0022034512451026">3B</xref>).</p>
<fig id="fig3-0022034512451026" position="float">
<label>Figure 3.</label>
<caption>
<p>Histological hematoxylin-and-eosin-stained photomicrographs of the bone structure surrounding M1 roots <bold>(A)</bold>. Changes in bone volume (BV)/total volume (TV) (n.s., not significant; *p &lt; 0.05; **p &lt; 0.01) <bold>(B)</bold>. Osteoclasts (arrows) along the bone surface of the M1 distobuccal root 14 days after spring insertion <bold>(C)</bold>. Comparison of changes in osteoclast count (OC) and bone surface (BS); n.s., not significant; *p &lt; 0.05; **p &lt; 0.01; ***p &lt; 0.001) <bold>(D)</bold>.</p>
</caption>
<graphic xlink:href="10.1177_0022034512451026-fig3.tif"/></fig>
<p>In the OPG−/− RM-A+ group, there was less prominent alveolar bone resorption in the trabecular bone of the furcation and interradicular septum around M1 than in the OPG−/− RM-A- group. In this group, the bone volume of the interradicular septum did not differ significantly from that of the WT RM-A- group (<xref ref-type="fig" rid="fig3-0022034512451026">Figs. 3A</xref>, <xref ref-type="fig" rid="fig3-0022034512451026">3B</xref>).</p>
</sec>
<sec id="section12-0022034512451026">
<title>RM-A Significantly Decreased Osteoclast Counts in Both WT and OPG −/− Mice</title>
<p>At 14 days, osteoclast counts were significantly higher in the OPG−/− RM-A- group than in the WT RM-A- group (<xref ref-type="fig" rid="fig3-0022034512451026">Figs. 3C</xref>, <xref ref-type="fig" rid="fig3-0022034512451026">3D</xref>). RM-A administration led to a significant decrease in osteoclast count in both the WT group (WT RM-A+ subgroup <italic>vs</italic>. WT RM-A- subgroup; p &lt; 0.01) and the OPG−/− group (OPG−/− RM-A+ subgroup <italic>vs</italic>. OPG−/− RM-A- subgroup; p &lt; 0.001), such that there was no significant difference between the WT RM-A- and OPG−/− RM-A+ groups (<xref ref-type="fig" rid="fig3-0022034512451026">Figs. 3C</xref>, <xref ref-type="fig" rid="fig3-0022034512451026">3D</xref>).</p>
</sec>
<sec id="section13-0022034512451026">
<title>RM-A Administration Significantly Lowered Serum ALP and TRAP Levels</title>
<p>Serum TRAP levels of the OPG−/− RM-A- group were significantly higher than those of the WT RM-A- group (p &lt; 0.01) (<xref ref-type="fig" rid="fig4-0022034512451026">Fig. 4A</xref>). In the OPG−/− group, RM-A administration significantly lowered serum TRAP levels (<xref ref-type="fig" rid="fig4-0022034512451026">Fig. 4A</xref>). There was no significant difference in serum TRAP levels between the OPG−/− RM-A+ and WT RM-A- groups.</p>
<fig id="fig4-0022034512451026" position="float">
<label>Figure 4.</label>
<caption>
<p>Mean serum TRAP activity in OPG−/− and WT mice 14 days after spring insertion (n.s., not significant; *p &lt; 0.05; **p &lt; 0.01) <bold>(A)</bold>. Mean serum ALP activity in OPG−/− and WT mice 14 days after spring insertion (n.s., not significant; *p &lt; 0.05; ***p &lt; 0.001) <bold>(B)</bold>.</p>
</caption>
<graphic xlink:href="10.1177_0022034512451026-fig4.tif"/></fig>
<p>Serum ALP levels of the OPG−/− RM-A- group were significantly higher than those of the WT RM-A- group (p &lt; 0.001) (<xref ref-type="fig" rid="fig4-0022034512451026">Fig. 4B</xref>). In the OPG−/− group, RM-A administration significantly lowered serum ALP levels but not to a level as low as that of the WT RM-A- group (<xref ref-type="fig" rid="fig4-0022034512451026">Fig. 4B</xref>). There was no significant difference in serum TRAP or ALP levels between the WT RM-A- and WT RM-A+ groups.</p>
</sec></sec>
<sec id="section14-0022034512451026" sec-type="discussion">
<title>Discussion</title>
<p>Our observations showed that orthodontic mechanical stress may enhance osteoclast activity and lead to imbalances in bone turnover activity. We also found that OPG−/− mice have high osteoclast activity and a mesh-like trabecular bone structure in the alveolar bone.</p>
<p>Our results suggested that increased alveolar bone resorption may occur if orthodontic treatment is administered to patients without systemic and local control. Previous studies have found that loss of systemic bone mineral density is related to the risk of periodontal disease progression and tooth loss (<xref ref-type="bibr" rid="bibr6-0022034512451026">Inagaki <italic>et al</italic>., 2005</xref>; <xref ref-type="bibr" rid="bibr22-0022034512451026">Yoshihara <italic>et al</italic>., 2011</xref>), and the bone mineral content of the jaws was shown to be more reduced with a significantly greater loss of periodontal attachment in osteoporosis patients than in the general population (<xref ref-type="bibr" rid="bibr19-0022034512451026">von Wowern <italic>et al</italic>., 1994</xref>). It is therefore important to monitor the effects of such treatment on periodontal tissue.</p>
<p>RM-A-based orthodontic treatment may be effective for patients with high-turnover osteoporosis. Moreover, previous studies showed that a functional bio-assay may have an application in monitoring the effects of therapy in bone disease and suggested the influence of BP treatment in osteoporosis patients, Paget’s disease patients, and OPG−/− mice (<xref ref-type="bibr" rid="bibr11-0022034512451026">Nakamura <italic>et al</italic>., 2003</xref>; <xref ref-type="bibr" rid="bibr3-0022034512451026">Dugard <italic>et al</italic>., 2005</xref>).</p>
<p>Our analysis of serum TRAP and ALP measurements suggests that RM-A and BP systemically inhibited osteoclast and osteoblast activity. ALP expression was also inhibited by treatment with RM-A, even though ALP is related to osteoblast activity. Although previous studies have revealed the effects of osteoblasts on osteoclasts, the reciprocal effects of osteoclasts on osteoblasts remain unclear. Further studies are therefore necessary to clarify this relationship. However, we hypothesized that osteoblast and osteoclast coupling most likely influences the reduction of osteoblast activity indirectly, and that the inhibition of osteoclast activity prevents resorption of alveolar bone.</p>
<p>BPs are synthetic analogues of pyrophosphate which act directly on osteoclasts to inhibit bone resorption (<xref ref-type="bibr" rid="bibr4-0022034512451026">Fleisch, 1998</xref>) and have been reported to have an anabolic effect on osteoblasts that increases cell proliferation and maturation (<xref ref-type="bibr" rid="bibr5-0022034512451026">Im <italic>et al</italic>., 2004</xref>). BPs were previously shown to inhibit alveolar bone resorption and reduce the amount of tooth movement, while maintaining trabeculae in a high-turnover OPG−/− mouse osteoporosis model of the response of bone to mechanical stress (<xref ref-type="bibr" rid="bibr17-0022034512451026">Shoji <italic>et al</italic>., 2010</xref>). Although BPs offer some advantages, they have a long half-life (<xref ref-type="bibr" rid="bibr7-0022034512451026">Lenart <italic>et al</italic>., 2008</xref>) and may cause bone to become more brittle, so it is important to understand the effects of long-term administration, the risk of increased bone fragility, and the appearance of small cracks or fractures (<xref ref-type="bibr" rid="bibr2-0022034512451026">Cheung <italic>et al</italic>., 2007</xref>; <xref ref-type="bibr" rid="bibr14-0022034512451026">Russell, 2007</xref>). Adverse dental side-effects from BPs have also been reported, including decreased tooth movement, impaired bone healing, and osteonecrosis in the jaw (<xref ref-type="bibr" rid="bibr24-0022034512451026">Zahrowski, 2007</xref>). In fact, this was reported to interfere with orthodontic results (<xref ref-type="bibr" rid="bibr13-0022034512451026">Rinchuse <italic>et al</italic>., 2007</xref>).</p>
<p>Since the long-term application of BPs may increase the risk of adverse effects, our study focused on RM-A. In fact, we achieved results similar to those obtained with the use of BPs, in that RM-A administration in OPG−/− mice promoted the systemic normalization of bone metabolism and local inhibition of osteoclast activity.</p>
<p>RM-A is metabolized rapidly without being concentrated in the bone matrix, unlike BPs. Not only is it therefore considered advantageous in minimizing side-effects, but also its rapid metabolism can be used to good effect in orthodontic treatment. For example, when a tooth needs to be moved, RM-A administration can be stopped then started again when sufficient movement has been achieved. However, further studies are necessary to understand fully how to control tooth movement pharmacologically. We anticipate that the future of dentistry will include the expansion of RM-A applications and improvements to methods of administration such as the use of ointments or direct injection.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="supported-by">
<p>This study was supported by a Grant-in-Aid for Scientific Research from the <grant-sponsor>Ministry of Education, Science and Culture of Japan</grant-sponsor> (<grant-num>22592305</grant-num>).</p>
</fn>
<fn fn-type="conflict">
<p>All authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bucay</surname><given-names>N</given-names></name>
<name><surname>Sarosi</surname><given-names>I</given-names></name>
<name><surname>Dunstan</surname><given-names>CR</given-names></name>
<name><surname>Morony</surname><given-names>S</given-names></name>
<name><surname>Tarpley</surname><given-names>J</given-names></name>
<name><surname>Capparelli</surname><given-names>C</given-names></name>
<etal/>
</person-group>. (<year>1998</year>). <article-title>Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification</article-title>. <source>Genes Dev</source> <volume>12</volume>:<fpage>1260</fpage>-<lpage>1268</lpage>.</citation>
</ref>
<ref id="bibr2-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cheung</surname><given-names>RK</given-names></name>
<name><surname>Leung</surname><given-names>KK</given-names></name>
<name><surname>Lee</surname><given-names>KC</given-names></name>
<name><surname>Chow</surname><given-names>TC</given-names></name>
</person-group> (<year>2007</year>). <article-title>Sequential non- traumatic femoral shaft fractures in a patient on long-term alendronate</article-title>. <source>Hong Kong Med J</source> <volume>13</volume>:<fpage>485</fpage>-<lpage>489</lpage>.</citation>
</ref>
<ref id="bibr3-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dugard</surname><given-names>MN</given-names></name>
<name><surname>Sharp</surname><given-names>CA</given-names></name>
<name><surname>Evans</surname><given-names>SF</given-names></name>
<name><surname>Williams</surname><given-names>JH</given-names></name>
<name><surname>Davie</surname><given-names>MW</given-names></name>
<name><surname>Marshall</surname><given-names>MJ</given-names></name>
</person-group> (<year>2005</year>). <article-title>A bio-assay for effectors of osteoclast differentiation in serum from patients with bone disease</article-title>. <source>Clin Chim Acta</source> <volume>356</volume>:<fpage>154</fpage>-<lpage>163</lpage>.</citation>
</ref>
<ref id="bibr4-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fleisch</surname><given-names>H</given-names></name>
</person-group> (<year>1998</year>). <article-title>Bisphosphonates: mechanisms of action</article-title>. <source>Endocr Rev</source> <volume>19</volume>:<fpage>80</fpage>-<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr5-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Im</surname><given-names>GI</given-names></name>
<name><surname>Qureshi</surname><given-names>SA</given-names></name>
<name><surname>Kenney</surname><given-names>J</given-names></name>
<name><surname>Rubash</surname><given-names>HE</given-names></name>
<name><surname>Shanbhag</surname><given-names>AS</given-names></name>
</person-group> (<year>2004</year>). <article-title>Osteoblast proliferation and maturation by bisphosphonates</article-title>. <source>Biomaterials</source> <volume>25</volume>:<fpage>4105</fpage>-<lpage>4115</lpage>.</citation>
</ref>
<ref id="bibr6-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Inagaki</surname><given-names>K</given-names></name>
<name><surname>Kurosu</surname><given-names>Y</given-names></name>
<name><surname>Yoshinari</surname><given-names>N</given-names></name>
<name><surname>Noguchi</surname><given-names>T</given-names></name>
<name><surname>Krall</surname><given-names>EA</given-names></name>
<name><surname>Garcia</surname><given-names>RI</given-names></name>
</person-group> (<year>2005</year>). <article-title>Efficacy of periodontal disease and tooth loss to screen for low bone mineral density in Japanese women</article-title>. <source>Calcif Tissue Int</source> <volume>77</volume>:<fpage>9</fpage>-<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr7-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lenart</surname><given-names>BA</given-names></name>
<name><surname>Lorich</surname><given-names>DG</given-names></name>
<name><surname>Lane</surname><given-names>JM</given-names></name>
</person-group> (<year>2008</year>). <article-title>Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate</article-title>. <source>N Engl J Med</source> <volume>358</volume>:<fpage>1304</fpage>-<lpage>1306</lpage>.</citation>
</ref>
<ref id="bibr8-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mizuno</surname><given-names>A</given-names></name>
<name><surname>Amizuka</surname><given-names>N</given-names></name>
<name><surname>Irie</surname><given-names>K</given-names></name>
<name><surname>Murakami</surname><given-names>A</given-names></name>
<name><surname>Fujise</surname><given-names>N</given-names></name>
<name><surname>Kanno</surname><given-names>T</given-names></name>
<etal/>
</person-group>. (<year>1998</year>). <article-title>Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin</article-title>. <source>Biochem Biophys Res Commun</source> <volume>247</volume>: <fpage>610</fpage>-<lpage>615</lpage>.</citation>
</ref>
<ref id="bibr9-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muguruma</surname><given-names>H</given-names></name>
<name><surname>Yano</surname><given-names>S</given-names></name>
<name><surname>Kakiuchi</surname><given-names>S</given-names></name>
<name><surname>Uehara</surname><given-names>H</given-names></name>
<name><surname>Kawatani</surname><given-names>M</given-names></name>
<name><surname>Osada</surname><given-names>H</given-names></name>
<etal/>
</person-group>. (<year>2005</year>). <article-title>Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity</article-title>. <source>Clin Cancer Res</source> <volume>11</volume>(<issue>24 Pt 1</issue>):<fpage>8822</fpage>-<lpage>8828</lpage>.</citation>
</ref>
<ref id="bibr10-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murakami</surname><given-names>H</given-names></name>
<name><surname>Takahashi</surname><given-names>N</given-names></name>
<name><surname>Sasaki</surname><given-names>T</given-names></name>
<name><surname>Udagawa</surname><given-names>N</given-names></name>
<name><surname>Tanaka</surname><given-names>S</given-names></name>
<name><surname>Nakamura</surname><given-names>I</given-names></name>
<etal/>
</person-group>. (<year>1995</year>). <article-title>A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders</article-title>. <source>Bone</source> <volume>17</volume>:<fpage>137</fpage>-<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr11-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nakamura</surname><given-names>M</given-names></name>
<name><surname>Udagawa</surname><given-names>N</given-names></name>
<name><surname>Matsuura</surname><given-names>S</given-names></name>
<name><surname>Mogi</surname><given-names>M</given-names></name>
<name><surname>Nakamura</surname><given-names>H</given-names></name>
<name><surname>Horiuchi</surname><given-names>H</given-names></name>
<etal/>
</person-group>. (<year>2003</year>). <article-title>Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption</article-title>. <source>Endocrinology</source> <volume>144</volume>:<fpage>5441</fpage>-<lpage>5449</lpage>.</citation>
</ref>
<ref id="bibr12-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Osada</surname><given-names>H</given-names></name>
<name><surname>Koshino</surname><given-names>H</given-names></name>
<name><surname>Isono</surname><given-names>K</given-names></name>
<name><surname>Takahashi</surname><given-names>H</given-names></name>
<name><surname>Kawanishi</surname><given-names>G</given-names></name>
</person-group> (<year>1991</year>). <article-title>Reveromycin A, a new antibiotic which inhibits the mitogenic activity of epidermal growth factor</article-title>. <source>J Antibiot (Tokyo)</source> <volume>44</volume>:<fpage>259</fpage>-<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr13-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rinchuse</surname><given-names>DJ</given-names></name>
<name><surname>Rinchuse</surname><given-names>DJ</given-names></name>
<name><surname>Sosovicka</surname><given-names>MF</given-names></name>
<name><surname>Robison</surname><given-names>JM</given-names></name>
<name><surname>Pendleton</surname><given-names>R</given-names></name>
</person-group> (<year>2007</year>) <article-title>Orthodontic treatment of patients using bisphosphonates: a report of 2 cases</article-title>. <source>Am J Orthod Dentofacial Orthop</source> <volume>131</volume>:<fpage>321</fpage>-<lpage>326</lpage>.</citation>
</ref>
<ref id="bibr14-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Russell</surname><given-names>RG</given-names></name>
</person-group> (<year>2007</year>). <article-title>Bisphosphonates: mode of action and pharmacology</article-title>. <source>Pediatrics</source> <volume>119</volume>(<supplement>Suppl 2</supplement>):<fpage>150</fpage>-<lpage>162</lpage>.</citation>
</ref>
<ref id="bibr15-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Russell</surname><given-names>RG</given-names></name>
<name><surname>Rogers</surname><given-names>MJ</given-names></name>
</person-group> (<year>1999</year>). <article-title>Bisphosphonates: from the laboratory to the clinic and back again</article-title>. <source>Bone</source> <volume>25</volume>:<fpage>97</fpage>-<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr16-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sato</surname><given-names>Y</given-names></name>
<name><surname>Sakai</surname><given-names>H</given-names></name>
<name><surname>Kobayashi</surname><given-names>Y</given-names></name>
<name><surname>Shibasaki</surname><given-names>Y</given-names></name>
<name><surname>Sasaki</surname><given-names>T</given-names></name>
</person-group> (<year>2000</year>). <article-title>Bisphosphonate administration alters subcellular localization of vacuolar-type H(+)-ATPase and cathepsin K in osteoclasts during experimental movement of rat molars</article-title>. <source>Anat Rec</source> <volume>260</volume>:<fpage>72</fpage>-<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr17-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shoji</surname><given-names>S</given-names></name>
<name><surname>Tabuchi</surname><given-names>M</given-names></name>
<name><surname>Miyazawa</surname><given-names>K</given-names></name>
<name><surname>Yabumoto</surname><given-names>T</given-names></name>
<name><surname>Tanaka</surname><given-names>M</given-names></name>
<name><surname>Kadota</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2010</year>). <article-title>Bisphosphonate inhibits bone turnover in OPG(−/−) mice via a depressive effect on both osteoclasts and osteoblasts</article-title>. <source>Calcif Tissue Int</source> <volume>87</volume>:<fpage>181</fpage>-<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr18-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sprogar</surname><given-names>S</given-names></name>
<name><surname>Vaupotic</surname><given-names>T</given-names></name>
<name><surname>Cor</surname><given-names>A</given-names></name>
<name><surname>Drevensek</surname><given-names>M</given-names></name>
<name><surname>Drevensek</surname><given-names>G</given-names></name>
</person-group> (<year>2008</year>). <article-title>The endothelin system mediates bone modeling in the late stage of orthodontic tooth movement in rats</article-title>. <source>Bone</source> <volume>43</volume>:<fpage>740</fpage>-<lpage>747</lpage>.</citation>
</ref>
<ref id="bibr19-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>von Wowern</surname><given-names>N</given-names></name>
<name><surname>Klausen</surname><given-names>B</given-names></name>
<name><surname>Kollerup</surname><given-names>G</given-names></name>
</person-group> (<year>1994</year>). <article-title>Osteoporosis: a risk factor in periodontal disease</article-title>. <source>J Periodontol</source> <volume>65</volume>:<fpage>1134</fpage>-<lpage>1138</lpage>.</citation>
</ref>
<ref id="bibr20-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Woo</surname><given-names>JT</given-names></name>
<name><surname>Kawatani</surname><given-names>M</given-names></name>
<name><surname>Kato</surname><given-names>M</given-names></name>
<name><surname>Shinki</surname><given-names>T</given-names></name>
<name><surname>Yonezawa</surname><given-names>T</given-names></name>
<name><surname>Kanoh</surname><given-names>N</given-names></name>
<etal/>
</person-group>. (<year>2006</year>). <article-title>Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>103</volume>:<fpage>4729</fpage>-<lpage>4734</lpage>.</citation>
</ref>
<ref id="bibr21-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yokoya</surname><given-names>K</given-names></name>
<name><surname>Sasaki</surname><given-names>T</given-names></name>
<name><surname>Shibasaki</surname><given-names>Y</given-names></name>
</person-group> (<year>1997</year>). <article-title>Distributional changes of osteoclasts and pre-osteoclastic cells in periodontal tissues during experimental tooth movement as revealed by quantitative immunohistochemistry of H(+)-ATPase</article-title>. <source>J Dent Res</source> <volume>76</volume>:<fpage>580</fpage>-<lpage>587</lpage>.</citation>
</ref>
<ref id="bibr22-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoshihara</surname><given-names>A</given-names></name>
<name><surname>Hayashi</surname><given-names>Y</given-names></name>
<name><surname>Miyazaki</surname><given-names>H</given-names></name>
</person-group> (<year>2011</year>). <article-title>Relationships among bone turnover, renal function and periodontal disease in elderly Japanese</article-title>. <source>J Periodontal Res</source> <volume>46</volume>:<fpage>491</fpage>-<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr23-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoshimatsu</surname><given-names>M</given-names></name>
<name><surname>Shibata</surname><given-names>Y</given-names></name>
<name><surname>Kitaura</surname><given-names>H</given-names></name>
<name><surname>Chang</surname><given-names>X</given-names></name>
<name><surname>Moriishi</surname><given-names>T</given-names></name>
<name><surname>Hashimoto</surname><given-names>F</given-names></name>
<etal/>
</person-group>. (<year>2006</year>). <article-title>Experimental model of tooth movement by orthodontic force in mice and its application to tumor necrosis factor receptor-deficient mice</article-title>. <source>J Bone Miner Metab</source> <volume>24</volume>:<fpage>20</fpage>-<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr24-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zahrowski</surname><given-names>JJ</given-names></name>
</person-group> (<year>2007</year>). <article-title>Bisphosphonate treatment: an orthodontic concern calling for a proactive approach</article-title>. <source>Am J Orthod Dentofacial Orthop</source> <volume>131</volume>:<fpage>311</fpage>-<lpage>320</lpage>.</citation>
</ref>
<ref id="bibr25-0022034512451026">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zahrowski</surname><given-names>JJ</given-names></name>
</person-group> (<year>2009</year>). <article-title>Optimizing orthodontic treatment in patients taking bisphosphonates for osteoporosis</article-title>. <source>Am J Orthod Dentofacial Orthop</source> <volume>135</volume>:<fpage>361</fpage>-<lpage>374</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>